Advanced Nanovehicle Delivery Systems for Oridonin in Cancer Therapy
Author Information
Author(s): Su Yilin, Liu Lisha, Lin Chongyang, Deng Dashi, Li Yunfei, Huang Mou, Wang Yu, Ling Kangqiu, Wang Haobing, Chen Qiyu, Huang Guixiao
Primary Institution: Institute of Urology, The Third Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, China
Hypothesis
Can advanced nanovehicle delivery systems improve the clinical applicability of oridonin in cancer therapy?
Conclusion
The review highlights the potential of oridonin-based nano-delivery systems to enhance bioavailability and reduce toxicity, although further research is needed for clinical implementation.
Supporting Evidence
- Oridonin has shown anticancer properties but is limited by poor solubility.
- Nanoparticles can improve drug delivery and targeting to tumor tissues.
- Various nanocarrier systems have been developed to enhance the bioavailability of oridonin.
Takeaway
Oridonin is a natural compound that can help fight cancer, but it doesn't dissolve well in water. Scientists are working on special delivery systems to help it work better in the body.
Methodology
This review summarizes various ORI delivery platforms and fabrication techniques, including nanoparticles, micelles, and liposomes.
Limitations
Current ORI delivery systems face challenges such as poor solubility, low bioavailability, and potential toxicity.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website